Page 9 - Mark Mintun News Today

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large...

Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large...

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large...

Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large...

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Another experimental Alzheimers drug can modestly slow patients inevitable worsening — by about four to seven months, researchers reported Monday.

Patients given monthly infusions of Eli Lilly and Co.'s donanemab declined about four to seven months more slowly than those given dummy infusions in a large...

Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.